GSA Capital Partners LLP Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Key Points

• GSA Capital Partners LLP increased its stake in Zentalis Pharmaceuticals by 275.9% in Q1, acquiring a total of 541,975 shares valued at approximately $862,000.
• Several analysts have rated Zentalis Pharmaceuticals with a consensus rating of "Moderate Buy", projecting a target price of $8.37, with HC Wainwright setting a more optimistic target of $10.00.
• Zentalis Pharmaceuticals reported earnings of ($0.67) per share for the last quarter, meeting analysts' expectations, with predictions for an annual EPS of ($2.42).

GSA Capital Partners LLP raised its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 275.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 541,975 shares of the company's stock after acquiring an additional 397,805 shares during the period. GSA Capital Partners LLP owned approximately 0.75% of Zentalis Pharmaceuticals worth $862,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at $68,000. Thrivent Financial for Lutherans grew its position in shares of Zentalis Pharmaceuticals by 155.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 70,641 shares of the company's stock valued at $214,000 after acquiring an additional 43,036 shares during the period. Sei Investments Co. purchased a new position in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $107,000. Prudential Financial Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $39,000. Finally, JPMorgan Chase & Co. raised its holdings in Zentalis Pharmaceuticals by 75.7% in the 4th quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock worth $2,605,000 after purchasing an additional 370,511 shares during the period.

Zentalis Pharmaceuticals Trading Down 2.9%

ZNTL traded down $0.04 during trading hours on Friday, hitting $1.34. 416,410 shares of the company's stock were exchanged, compared to its average volume of 772,347. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.01 and a 12-month high of $5.44. The firm has a market cap of $96.41 million, a P/E ratio of -0.43 and a beta of 1.71. The firm has a 50 day moving average of $1.36 and a 200 day moving average of $1.58.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.67). As a group, research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Analysts Set New Price Targets

ZNTL has been the topic of several research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Wedbush reissued a "neutral" rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.37.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.